Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.
| Ticker |
Sentiment |
Impact |
|
UHS
|
Somewhat Bullish
|
32 %
|
|
ABM
|
Neutral
|
22 %
|
|
DCTH
|
Bullish
|
47 %
|
|
DGX
|
Somewhat Bullish
|
27 %
|
